{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:50:10Z","timestamp":1793296210462,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ncl.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:11:33Z","timestamp":1760533893000},"page":"47-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Placebo Responses in Trials of Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"44","author":[{"given":"Surabhi","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ncl.2025.08.003_bib1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/mds.27438","article-title":"Neurobiology of placebo effect in Parkinson\u2019s disease: what we have learned and where we are going","volume":"33","author":"Quattrone","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2025.08.003_bib2","first-page":"187","volume":"153","author":"Lou","year":"2020"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.003_bib3","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/mds.27476","article-title":"The placebo response in Parkinson\u2019s disease and other movement disorders","volume":"33","author":"Mestre","year":"2018","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.003_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/mds.21894","article-title":"Placebo response in Parkinson\u2019s disease: comparisons among 11 trials covering medical and surgical interventions","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.003_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0165-0173(99)00023-5","article-title":"The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking","volume":"31","author":"Ikemoto","year":"1999","journal-title":"Brain Res Brain Res Rev"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.003_bib6","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/mds.27416","article-title":"What influences placebo and nocebo responses in parkinson\u2019s disease?","volume":"33","author":"Witek","year":"2018","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.003_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/mds.27409","article-title":"Harnessing the power of placebos in movement disorders: insights from Parkinson\u2019s disease in clinical research and practice","volume":"33","author":"Mestre","year":"2018","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.003_bib8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.54.3.710","article-title":"Objective changes in motor function during placebo treatment in PD","volume":"54","author":"Goetz","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.003_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mds.10024","article-title":"Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson\u2019s disease","volume":"17","author":"Goetz","year":"2002","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.003_bib10","first-page":"1653","article-title":"Functional brain networks to evaluate treatment responses in parkinson\u2019s disease","volume":"20","author":"Barbero","year":"2023","journal-title":"Neurother J Am Soc Exp Neurother"},{"issue":"19","key":"10.1016\/j.ncl.2025.08.003_bib11","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1113\/JP271322","article-title":"Teaching neurons to respond to placebos","volume":"594","author":"Benedetti","year":"2016","journal-title":"J Physiol"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.003_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in parkinson\u2019s disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"9916","key":"10.1016\/j.ncl.2025.08.003_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.003_bib14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/01.wnl.0000324635.49971.3d","article-title":"The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies","volume":"71","author":"Diederich","year":"2008","journal-title":"Neurology"},{"issue":"5532","key":"10.1016\/j.ncl.2025.08.003_bib15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1126\/science.1060937","article-title":"Expectation and dopamine release: mechanism of the placebo effect in Parkinson\u2019s disease","volume":"293","author":"de la Fuente-Fern\u00e1ndez","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.003_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0166-4328(02)00130-4","article-title":"Dopamine release in human ventral striatum and expectation of reward","volume":"136","author":"de la Fuente-Fern\u00e1ndez","year":"2002","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.003_bib17","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.neuroimage.2006.02.005","article-title":"Therapeutic application of transcranial magnetic stimulation in Parkinson\u2019s disease: the contribution of expectation","volume":"31","author":"Strafella","year":"2006","journal-title":"Neuroimage"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.003_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nn1250","article-title":"Placebo-responsive parkinson patients show decreased activity in single neurons of subthalamic nucleus","volume":"7","author":"Benedetti","year":"2004","journal-title":"Nat Neurosci"},{"issue":"34","key":"10.1016\/j.ncl.2025.08.003_bib19","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1523\/JNEUROSCI.0439-05.2005","article-title":"Placebo effects mediated by endogenous opioid activity on mu-opioid receptors","volume":"25","author":"Zubieta","year":"2005","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.003_bib20","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1172\/JCI75073","article-title":"Network modulation following sham surgery in Parkinson\u2019s disease","volume":"124","author":"Ko","year":"2014","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.003_bib21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/mds.25471","article-title":"Effect of expectancy and personality on cortical excitability in Parkinson\u2019s disease","volume":"28","author":"Lou","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2025.08.003_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.parkreldis.2016.05.019","article-title":"Predictors of the placebo response in clinical trials on Parkinson\u2019s disease: a meta-analysis","volume":"29","author":"Shin","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2025.08.003_bib23","first-page":"153","volume":"Vol. 2","author":"Fahn","year":"1987"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.003_bib24","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","article-title":"A multicenter controlled clinical trial in early parkinson\u2019s disease: parkinson study group","volume":"46","year":"1989","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.003_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/mds.10024","article-title":"Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson\u2019s disease","volume":"17","author":"Goetz","year":"2002","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.003_bib26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.410410111","article-title":"Which clinical sign of Parkinson\u2019s disease best reflects the nigrostriatal lesion?","volume":"41","author":"Vingerhoets","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2025.08.003_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2018.03.012","article-title":"The placebo effect on resting tremor in Parkinson\u2019s disease: an electrophysiological study","volume":"52","author":"Barbagallo","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2025.08.003_bib28","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1353-8020(11)70027-X","article-title":"Parkinson\u2019s disease tremor: pathophysiology","volume":"18","author":"Hallett","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2025.08.003_bib29","first-page":"S492","article-title":"A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of L-dopa-unduced dyskinesia associated with Parkinson\u2019s disease: The Paddy-1 study: P606","volume":"21","author":"Rascol","year":"2006","journal-title":"Movement disorders"},{"key":"10.1016\/j.ncl.2025.08.003_bib30","first-page":"S591","article-title":"The PADDY-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in Parkinson\u2019s disease patients: P953","volume":"21","author":"M\u00fcller","year":"2006","journal-title":"Movement Disorders"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.003_bib31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.003_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat Neurosci"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.003_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/WCO.0000000000000112","article-title":"Premotor and non-motor features of Parkinson\u2019s disease","volume":"27","author":"Goldman","year":"2014","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.003_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1176\/appi.neuropsych.11090210","article-title":"Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson\u2019s disease?","volume":"24","author":"Zahodne","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12_suppl_4","key":"10.1016\/j.ncl.2025.08.003_bib35","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.65.12_suppl_4.S7","article-title":"Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain","volume":"65","author":"Dworkin","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.003_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.NMD.0000061144.16176.38","article-title":"Placebo response and antidepressant clinical trial outcome","volume":"191","author":"Khan","year":"2003","journal-title":"J Nerv Ment Dis"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.003_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079510","article-title":"A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in parkinson\u2019s disease","volume":"8","author":"Troeung","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.003_bib38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881113478282","article-title":"Antidepressants for depression in Parkinson\u2019s disease: systematic review and meta-analysis","volume":"27","author":"Rocha","year":"2013","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"22","key":"10.1016\/j.ncl.2025.08.003_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006698","article-title":"Efficacy of antidepressive medication for depression in parkinson disease: a network meta-analysis","volume":"96","author":"Zhuo","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.003_bib40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/appi.ajp.159.5.728","article-title":"The functional neuroanatomy of the placebo effect","volume":"159","author":"Mayberg","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.003_bib41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamapsychiatry.2015.1335","article-title":"Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression","volume":"72","author":"Peci\u00f1a","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.003_bib42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.37349\/ent.2023.00036","article-title":"Pathophysiology of non-motor signs in parkinsons disease: some recent updating with brief presentation","volume":"3","author":"Radad","year":"2023","journal-title":"Explor Neuroprotective Ther"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.003_bib43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archpsyc.61.4.412","article-title":"Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial","volume":"61","author":"McRae","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.003_bib44","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/00001756-200208070-00006","article-title":"Expectation modulates the response to subthalamic nucleus stimulation in parkinsonian patients","volume":"13","author":"Pollo","year":"2002","journal-title":"Neuroreport"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.003_bib45","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/mds.20935","article-title":"Expectation and the placebo effect in Parkinson\u2019s disease patients with subthalamic nucleus deep brain stimulation","volume":"21","author":"Mercado","year":"2006","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"10.1016\/j.ncl.2025.08.003_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bbr.2013.04.051","article-title":"Motor and cognitive placebo-\/nocebo-responses in Parkinson\u2019s disease patients with deep brain stimulation","volume":"250","author":"Keitel","year":"2013","journal-title":"Behav Brain Res"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.003_bib47","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/mds.27142","article-title":"The placebo effect on bradykinesia in Parkinson\u2019s disease with and without prior drug conditioning","volume":"32","author":"Frisaldi","year":"2017","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.003_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.molmed.2015.02.009","article-title":"Genetics and the placebo effect: the placebome","volume":"21","author":"Hall","year":"2015","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.003_bib49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenetics"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.003_bib50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ana.22155","article-title":"The COMT Val158Met polymorphism affects the response to entacapone in Parkinson\u2019s disease: a randomized crossover clinical trial","volume":"69","author":"Corvol","year":"2011","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.003_bib51","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archgenpsychiatry.2010.88","article-title":"Effects of expectation on placebo-induced dopamine release in parkinson disease","volume":"67","author":"Lidstone","year":"2010","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.003_bib52","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/mds.10504","article-title":"Impact of placebo assignment in clinical trials of Parkinson\u2019s disease","volume":"18","author":"Goetz","year":"2003","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"10.1016\/j.ncl.2025.08.003_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbr.2015.12.021","article-title":"Placebo effects induced by auditory cues decrease parkinsonian rigidity in patients with subthalamic stimulation","volume":"301","author":"R\u00e4tsep","year":"2016","journal-title":"Behav Brain Res"},{"issue":"13","key":"10.1016\/j.ncl.2025.08.003_bib54","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMoa000827","article-title":"Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson\u2019s disease","volume":"345","author":"Deep Brain Stimulation for Parkinson\u2019s Disease Study Group","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.003_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.parkreldis.2003.10.003","article-title":"Uncovering the hidden placebo effect in deep-brain stimulation for Parkinson\u2019s disease","volume":"10","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Parkinsonism Relat Disord"},{"issue":"14","key":"10.1016\/j.ncl.2025.08.003_bib56","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/mds.26080","article-title":"Myths and facts about the EARLYSTIM study","volume":"29","author":"Sch\u00fcpbach","year":"2014","journal-title":"Mov Disord Off J Mov Disord Soc"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.003_bib57","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1212\/WNL.0000000000001282","article-title":"Placebo effect of medication cost in parkinson disease: a randomized double-blind study","volume":"84","author":"Espay","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.08.003_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.parkreldis.2017.02.003","article-title":"A randomized trial of relamorelin for constipation in Parkinson\u2019s disease (MOVE-PD): trial results and lessons learned","volume":"37","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2025.08.003_bib59","unstructured":"Friedman JH, Ravina B, Mills R, et al. A multicenter, placebo controlled, double blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson\u2019s disease. Neurol, 2010;77(Abstr 1):S1."},{"issue":"6","key":"10.1016\/j.ncl.2025.08.003_bib60","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nn1250","article-title":"Placebo-responsive parkinson patients show decreased activity in single neurons of subthalamic nucleus","volume":"7","author":"Benedetti","year":"2004","journal-title":"Nat Neurosci"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.003_bib61","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.bbi.2005.06.004","article-title":"Expectation enhances autonomic responses to stimulation of the human subthalamic limbic region","volume":"19","author":"Lanotte","year":"2005","journal-title":"Brain Behav Immun"},{"issue":"22","key":"10.1016\/j.ncl.2025.08.003_bib62","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJM197905313002203","article-title":"A new design for randomized clinical trials","volume":"300","author":"Zelen","year":"1979","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.003_bib63","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","article-title":"A randomized trial of deep-brain stimulation for Parkinson\u2019s disease","volume":"355","author":"Deuschl","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.003_bib64","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1205158","article-title":"Neurostimulation for Parkinson\u2019s disease with early motor complications","volume":"368","author":"Schuepbach","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2025.08.003_bib65","article-title":"Patients\u2019 preferences within randomised trials: systematic review and patient level meta-analysis","volume":"337","year":"2008","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.ncl.2025.08.003_bib66","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/mds.26024","article-title":"Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson\u2019s disease-the EARLYSTIM trial: early is not always better","volume":"29","author":"Mestre","year":"2014","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"10.1016\/j.ncl.2025.08.003_bib67","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1146\/annurev-psych-010418-102907","article-title":"Psychobiological mechanisms of placebo and nocebo effects: pathways to improve treatments and reduce side effects","volume":"70","author":"Petrie","year":"2019","journal-title":"Annu Rev Psychol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T22:47:57Z","timestamp":1763074077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0733861925000532"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.003","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo Responses in Trials of Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}